The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract

Research output: Contribution to journalReview article

46 Citations (Scopus)

Abstract

Although no serological tumor marker has yet been shown to be sufficiently sensitive and specific to be used in screening for colorectal, gastric, or pancreatic cancers, elevated pre-operative levels of carcinoembryonic antigen and carbohydrate antigen (CA) 19-9 correlate with advanced stages of disease and a poorer clinical outcome. Monitoring of serum carcinoembryonic antigen after primary resection of colorectal cancer may identify a small percentage of asymptomatic patients with recurrent disease who are amenable to a second surgical procedure with curative intent. A new class of turner markers that recognize cytokeratins, which comprise the intermediate filaments of the cytoskeletons of epithelial cells, is being evaluated as a prognostic factor in colorectal and gastric cancer. Elevated mRNA expression of matrix metalloproteinases and their inhibitors in tumor tissue compared with normal intestinal mucosa predicts for a poor prognosis after primary management of colorectal cancer. CA 19-9, CA 72-4, and CYFRA 21-1 may convey prognostic information in gastric cancer. CA 19-9 appears to be the best overall tumor marker for pancreatic cancer, and a subsequent rise after postoperative normalization may preceed clinical detection of recurrent disease. CAM 17.1 is a new marker that has similar sensitivity but better specificity than CA 19-9 in pancreatic cancer. The utility of serial monitoring of these tumor markers in patients with advanced disease is less well established but may become helpful if more effective systemic therapy is developed.

Original languageEnglish (US)
Pages (from-to)380-387
Number of pages8
JournalCurrent Opinion in Oncology
Volume9
Issue number4
DOIs
StatePublished - Jan 1 1997

Fingerprint

Tumor Biomarkers
Gastrointestinal Tract
Colorectal Neoplasms
Adenocarcinoma
Pancreatic Neoplasms
Carbohydrates
Stomach Neoplasms
Antigens
Carcinoembryonic Antigen
Matrix Metalloproteinase Inhibitors
Intermediate Filaments
Intestinal Mucosa
Keratins
Cytoskeleton
Epithelial Cells
Sensitivity and Specificity
Messenger RNA
Serum
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract. / Grem, Jean L.

In: Current Opinion in Oncology, Vol. 9, No. 4, 01.01.1997, p. 380-387.

Research output: Contribution to journalReview article

@article{1b3c262a778b4c54a2cb3d07098082f4,
title = "The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract",
abstract = "Although no serological tumor marker has yet been shown to be sufficiently sensitive and specific to be used in screening for colorectal, gastric, or pancreatic cancers, elevated pre-operative levels of carcinoembryonic antigen and carbohydrate antigen (CA) 19-9 correlate with advanced stages of disease and a poorer clinical outcome. Monitoring of serum carcinoembryonic antigen after primary resection of colorectal cancer may identify a small percentage of asymptomatic patients with recurrent disease who are amenable to a second surgical procedure with curative intent. A new class of turner markers that recognize cytokeratins, which comprise the intermediate filaments of the cytoskeletons of epithelial cells, is being evaluated as a prognostic factor in colorectal and gastric cancer. Elevated mRNA expression of matrix metalloproteinases and their inhibitors in tumor tissue compared with normal intestinal mucosa predicts for a poor prognosis after primary management of colorectal cancer. CA 19-9, CA 72-4, and CYFRA 21-1 may convey prognostic information in gastric cancer. CA 19-9 appears to be the best overall tumor marker for pancreatic cancer, and a subsequent rise after postoperative normalization may preceed clinical detection of recurrent disease. CAM 17.1 is a new marker that has similar sensitivity but better specificity than CA 19-9 in pancreatic cancer. The utility of serial monitoring of these tumor markers in patients with advanced disease is less well established but may become helpful if more effective systemic therapy is developed.",
author = "Grem, {Jean L}",
year = "1997",
month = "1",
day = "1",
doi = "10.1097/00001622-199709040-00012",
language = "English (US)",
volume = "9",
pages = "380--387",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - The prognostic importance of tumor markers in adenocarcinomas of the gastrointestinal tract

AU - Grem, Jean L

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Although no serological tumor marker has yet been shown to be sufficiently sensitive and specific to be used in screening for colorectal, gastric, or pancreatic cancers, elevated pre-operative levels of carcinoembryonic antigen and carbohydrate antigen (CA) 19-9 correlate with advanced stages of disease and a poorer clinical outcome. Monitoring of serum carcinoembryonic antigen after primary resection of colorectal cancer may identify a small percentage of asymptomatic patients with recurrent disease who are amenable to a second surgical procedure with curative intent. A new class of turner markers that recognize cytokeratins, which comprise the intermediate filaments of the cytoskeletons of epithelial cells, is being evaluated as a prognostic factor in colorectal and gastric cancer. Elevated mRNA expression of matrix metalloproteinases and their inhibitors in tumor tissue compared with normal intestinal mucosa predicts for a poor prognosis after primary management of colorectal cancer. CA 19-9, CA 72-4, and CYFRA 21-1 may convey prognostic information in gastric cancer. CA 19-9 appears to be the best overall tumor marker for pancreatic cancer, and a subsequent rise after postoperative normalization may preceed clinical detection of recurrent disease. CAM 17.1 is a new marker that has similar sensitivity but better specificity than CA 19-9 in pancreatic cancer. The utility of serial monitoring of these tumor markers in patients with advanced disease is less well established but may become helpful if more effective systemic therapy is developed.

AB - Although no serological tumor marker has yet been shown to be sufficiently sensitive and specific to be used in screening for colorectal, gastric, or pancreatic cancers, elevated pre-operative levels of carcinoembryonic antigen and carbohydrate antigen (CA) 19-9 correlate with advanced stages of disease and a poorer clinical outcome. Monitoring of serum carcinoembryonic antigen after primary resection of colorectal cancer may identify a small percentage of asymptomatic patients with recurrent disease who are amenable to a second surgical procedure with curative intent. A new class of turner markers that recognize cytokeratins, which comprise the intermediate filaments of the cytoskeletons of epithelial cells, is being evaluated as a prognostic factor in colorectal and gastric cancer. Elevated mRNA expression of matrix metalloproteinases and their inhibitors in tumor tissue compared with normal intestinal mucosa predicts for a poor prognosis after primary management of colorectal cancer. CA 19-9, CA 72-4, and CYFRA 21-1 may convey prognostic information in gastric cancer. CA 19-9 appears to be the best overall tumor marker for pancreatic cancer, and a subsequent rise after postoperative normalization may preceed clinical detection of recurrent disease. CAM 17.1 is a new marker that has similar sensitivity but better specificity than CA 19-9 in pancreatic cancer. The utility of serial monitoring of these tumor markers in patients with advanced disease is less well established but may become helpful if more effective systemic therapy is developed.

UR - http://www.scopus.com/inward/record.url?scp=0030849170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030849170&partnerID=8YFLogxK

U2 - 10.1097/00001622-199709040-00012

DO - 10.1097/00001622-199709040-00012

M3 - Review article

VL - 9

SP - 380

EP - 387

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 4

ER -